ArticleThe Korean journal of internal medicine2018
Management of carbapenem-resistant Acinetobacter baumannii epidemic in an intensive care unit using multifaceted intervention strategy.
Article in The Korean journal of internal medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 16 citations in OpenAlex.
- Effect of daily pillow cover replacement on the incidence of carbapenem resistant Acinetobacter baumannii (CRAB) in the medical intensive care units (MICU): a comparative study.Antimicrobial resistance and infection control · 2026Article
- Ward microclimate and procedural factors as predictors for CRAB environmental contamination in ICUs: a longitudinal monitoring study.Antimicrobial resistance and infection control · 2026Article
- An integrative review on the risk factors, prevention, and control strategies for carbapenem-resistantFrontiers in microbiology · 2024Review
- Control of Healthcare-Associated Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2022Article
- Identifying Targets for Antibiotic Use for the Management of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2022Article
- Urgent need for novel antibiotics in Republic of Korea to combat multidrug-resistant bacteria.The Korean journal of internal medicine · 2022Review
- Carbapenem-resistantFrontiers in microbiology · 2022Review
- Successful Incidences of Controlling Multidrug-Resistant, Extensively Drug-Resistant, and Nosocomial InfectionInfection and drug resistance · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsWe evaluated the effects of a multifaceted intervention for controlling a carbapenem-resistant Acinetobacter baumannii (CRAB) epidemic in an intensive care unit (ICU) with no restrictions on carbapenem use.
methodsThis study was conducted in a medical ICU between April 2012 and June 2016. The baseline infection control programs included surveillance cultures, contact precautions, and environmental cleaning. However, increases in the detection of CRAB isolates beginning in May 2013 led to the implementation of a new protocol, consisting of universal glove and gown use with daily chlorhexidine bathing for all patients in combination with baseline programs. The efficacy of the intervention was subjected to interrupted time series (ITS) analysis.
resultsThe multifaceted intervention led to a decrease in the incidence of CRAB from 17.65 to 0.89 cases per 1,000 patient-days, during the study period (p < 0.001). ITS analysis revealed a significant change in the trend of CRAB incidence (-0.413, p < 0.001). Over this same period, mean monthly use of carbapenems increased from 143.54 ± 95.73 to 204.95 ± 78.43 doses per 1,000 patient-days (p = 0.018).
conclusionOur multifaceted intervention reduced the incidence of CRAB acquisition in an ICU where carbapenem use was not restricted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.